Statins may cause rare instances of eye disorders
By Michelle Rizzo
NEW YORK (Reuters Health) - Treatment with a cholesterol-lowering “statin” drug may very occasionally cause double-vision, eyelid-droop, or weakness of the muscles that control eye movement, investigators report..
Dr. F. W. Fraunfelder and Dr. Amanda B. Richards, from the Casey Eye Institute, Oregon Health & Science University, Portland, investigated adverse events of this type documented in three large databases and report their findings in the medical journal Ophthalmology.
The team identified a total of 256 case reports of eye-muscle disorders associated with statins — which include drugs such as Lipitor, Zocor, or Crestor, for example.
The average dose of the statins was within the range recommended for each medication. The average time from starting on the statin to the occurrence of the eye problem was 8 months.
Among the 256 case reports, 62 patients stopped taking the statin and the double-vision or eyelid-droop resolved, Fraunfelder told Reuters Health. “Sixteen case reports indicate that the statin was started again and the (problem) reoccurred,” he said. “This is positive re-challenge data and very compelling evidence that a real adverse drug reaction occurred with statins.”
The side effect is rare, however. It’s known that statins can sometimes cause inflammation of skeletal muscles (myositis) in the body, and the current side effect “probably represents a localized myositis in the extraocular muscles,” Fraunfelder noted.
SOURCE: Ophthalmology, December 2008.
--------------------------------------------------------------------------------------------Related Posts:
NEW YORK (Reuters Health) - In the largest cohort study to date, treatment with a cholesterol-lowering statin drug was found to reduce new cases of Alzheimer’s disease, regardless of the specific type of statin used or a person’s genetic risk for the disease. Numerous studies have looked at the relationship between statin use and the development
Full Post: New study supports statin’s anti-dementia effects
--------------------------------------------------------------------------------------------
By Will Dunham WASHINGTON (Reuters) - Nearly 20 percent more U.S. men over 50 and women over 60 stand to benefit from taking statins, based on the findings of a recent study on the cholesterol-lowering drugs, U.S. researchers said on Tuesday. Their research stakes out a potentially expanded market for statins, already the world’s top-selling drugs. The so-called
Full Post: Statins may help millions more people: study
--------------------------------------------------------------------------------------------
CHICAGO (Reuters) - More than 1 billion people globally suffer from a condition in which the eye’s lens loses flexibility, blurring objects close by, and half of them do not own eyeglasses to help them see, researchers said on Monday. In 2005, an estimated 517 million people with presbyopia — which is thought to be caused
Full Post: Millions need eyeglasses but don’t have them
--------------------------------------------------------------------------------------------
BOSTON (Reuters) - Allergan Inc, maker of Botox, said on Friday that the U.S. Food and Drug Administration has approved its eyelash-thickening drug Latisse. Latisse is designed to treat a condition known as hypotrichosis of the eyelashes, in which a person has does not have enough eyelashes. The active ingredient in Latisse is bimatroprost, the same ingredient
Full Post: FDA approves Allergan’s drug for longer eyelashes
--------------------------------------------------------------------------------------------
By Anne Harding NEW YORK (Reuters Health) - Instituting a law requiring drivers who are 80 years old or older to have their eyes checked reduced fatalities among these motorists, new research from Florida shows. “Vision rescreening laws appear to be effective, but why they’re effective remains an unanswered question,” Dr. Gerald McGwin, Jr. of the University
Full Post: Vision tests cut death rates for older drivers